Drugs / DLBS3233
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07403201 | Dec 2021 → Jan 2026 overdue | polycystic ovary syndrome | Inlacinpenelitian | Recruiting | No outcome recorded |
| Phase 35 trials | ||||||
| Phase 3 | NCT01999686 | Oct 2014 → Feb 2019 | polycystic ovary syndrome | Dexa Medica Group | Completed | No outcome recorded |
| Phase 3 | NCT01733459 | Mar 2013 → Apr 2018 | polycystic ovary syndrome | Dexa Medica Group | Completed | No outcome recorded |
| Phase 3 | NCT01645332 | Jul 2012 → Aug 2014 | type 2 diabetes mellitus | Dexa Medica Group | Completed | No outcome recorded |
| Phase 3 | NCT01531933 | Nov 2011 → Jul 2012 | prediabetes syndrome | Dexa Medica Group | Completed | No outcome recorded |
| Phase 3 | NCT01472614 | Sep 2011 → Jan 2013 | type 2 diabetes mellitus | Dexa Medica Group | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DLBS3233 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01472614 ↗ |
| Modality | Traditional medicine (herbal / TCM) | “DLBS3233 itself is the new insulin-sensitizing drug, a combination-bioactive-fraction derived from two Indonesian herbals” PMID 37424700 ↗ Jul 2023 |
| Route | Oral | “1 DLBS3233 capsule 100 mg (once daily)” NCT01733459 ↗ |